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Abstract
It is still unclear how genetic information, provided as single‐nucleotide poly-
morphisms (SNPs), can be most effectively integrated into risk prediction models
for coronary heart disease (CHD) to add significant predictive value beyond clinical
risk models. For the present study, a population‐based case‐cohort was used as a
trainingset (451 incident cases, 1488 noncases) and an independent cohort as testset
(160 incident cases, 2749 noncases). The following strategies to quantify genetic
information were compared: A weighted genetic risk score including Metabochip
SNPs associated with CHD in the literature (GRSMetabo); selection of the most
predictive SNPs among these literature‐confirmed variants using priority‐Lasso
(PLMetabo); validation of two comprehensive polygenic risk scores: GRSGola based on
Metabochip data, and GRSKhera (available in the testset only) based on cross‐
validated genome‐wide genotyping data. We used Cox regression to assess asso-
ciations with incident CHD. C‐index, category‐free net reclassification index
(cfNRI) and relative integrated discrimination improvement (IDIrel) were used to
quantify the predictive performance of genetic information beyond Framingham
risk score variables. In contrast to GRSMetabo and PLMetabo, GRSGola significantly
improved the prediction (delta C‐index [95% confidence interval]: 0.0087 [0.0044,
0.0130]; IDIrel: 0.0509 [0.0131, 0.0894]; cfNRI improved only in cases: 0.1761
[0.0253, 0.3219]). GRSKhera yielded slightly worse prediction results than GRSGola.
KEYWORD S
coronary heart disease, Framingham risk score, genomic risk prediction, Metabochip,
priority‐Lasso
1 | INTRODUCTION
Coronary heart disease (CHD) is the leading cause of
death worldwide (Global Health Estimates 2016, 2018).
People at high risk for CHD can benefit from lifestyle or
pharmacologic interventions, even if the risk is of genetic
origin (Abraham et al., 2016; Damask et al., 2020; Khera
et al., 2016; Mega et al., 2015). Therefore, reliable predic-
tion models are needed. Genetic information may add
predictive value to established clinical risk models like the
Framingham risk score (FRS) (D'Agostino et al., 2008). In
the last few years, high‐throughput genotyping has be-
come more and more cost‐effective (Schwarze et al., 2018;
Wetterstrand, 2020). Genetic prediction modeling has
several advantages compared to prediction based on blood
biomarkers, such as proteins and metabolites (Herder,
Karakas, et al., 2011). Genotyping needs to be carried out
only once in a lifetime and its results can be used to de-
termine the risk of various diseases. Moreover, risk as-
sessment can be performed early in life, when lifestyle
changes are likely to have the greatest impact.
The field is evolving rapidly and there is an ongoing
debate on how genetic information, provided as single‐
nucleotide polymorphisms (SNPs), can be most effectively
integrated into predictive models for complex diseases like
CHD. The genetic information can be integrated in the form
of (weighted) genetic risk scores (GRS) consisting of pre-
selected variants (Antiochos et al., 2016; Beaney et al., 2017;
Elliott et al., 2020; Inouye et al., 2018; Iribarren et al., 2016;
R. W. Morris et al., 2016; Paynter et al., 2010; Said et al.,
2018; Tada et al., 2016; de Vries et al., 2015). Machine
Learning approaches without score formation are alter-
natively applied (Boulesteix et al., 2020; Dogan et al., 2018;
Gola et al., 2020; Okser et al., 2014). Apart from the method
of inclusion, studies vary regarding the utilized genotyping
tool. Predictive SNPs may stem from genome‐wide SNP ar-
ray data or specialized genotyping arrays such as the Meta-
bochip, which focuses on SNPs associated with
cardiometabolic outcomes (Voight et al., 2012).
Until recently, genetic risk prediction studies on complex
diseases focused on variants identified as significantly asso-
ciated in genome‐wide association studies (GWAS) or can-
didate gene association studies (Müller et al., 2016). Studies
on cardiovascular disease‐related events included only a few
literature‐based confirmed SNPs in their analyses to in-
vestigate the predictive value of genetic information in
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addition to established risk prediction models (Antiochos
et al., 2016; Beaney et al., 2017; Iribarren et al., 2016; R. W.
Morris et al., 2016; Paynter et al., 2010; Said et al., 2018; Tada
et al., 2016; de Vries et al., 2015). More recent studies showed
that taking into consideration a larger number of SNPs tends
to give more accurate prediction results beyond established
risk factors than including only genome‐wide significant
SNPs (Abraham et al., 2016; Elliott et al., 2020; Inouye
et al., 2018; Mars et al., 2020). Khera et al. (2018) derived a
polygenic risk score for coronary artery disease, based on
genome‐wide SNP array data. It has been repeatedly eval-
uated in several different studies and can therefore be re-
garded as a benchmark in coronary artery disease risk
prediction (Aragam et al., 2020; Dikilitas et al., 2020; Hindy
et al., 2020; Mosley et al., 2020; Wünnemann et al., 2019).
Another comprehensive polygenic risk score previously de-
rived by Gola et al. (2020) based on Metabochip data, was
reported to yield even better prediction results. However, the
Gola et al. (2020) results lack sufficient external investigation
and comparison.
The aim of the present study is to compare the ability of
different genetic risk quantification approaches to improve
the accuracy of CHD prediction beyond the established FRS
variables, including the recently published Gola score.
2 | METHODS
2.1 | Study populations
We used data from a prospective case‐cohort study in-
corporated within the population‐based Monitoring of
Trends and Determinants in Cardiovascular Diseases/
Cooperative Health Research in the Region of Augsburg
(MONICA/KORA) study as a training data set. This study
was initiated in the early 1980s by the World Health Or-
ganization. Details of design and procedures of this study
have been described elsewhere (Herder, Baumert,
et al., 2011; Koenig et al., 2006; Thorand et al., 2005;
Tunstall‐Pedoe & WHO MONICA Project Principal In-
vestigators, 1988). Briefly, for the original cohort study,
three independent cross‐sectional population‐based sur-
veys were conducted in the years 1984/1985 (Survey S1),
1989/1990 (S2), and 1994/1995 (S3) in Augsburg and two
adjacent counties in Southern Germany. In total 13,427
individuals (6725 men and 6702 women) aged 25–64 (S1)
or 25–74 years (S2, S3) participated at baseline.
As test data set, we used data from the population‐based
KORA S4 cohort study. The cross‐sectional baseline survey
was performed in 1999–2001 in the same study region as the
MONICA/KORA S1–S3 cohort study. In total 4261 in-
dividuals (2090 men and 2171 women) aged 25–74 years
participated at baseline (Ward‐Caviness et al., 2017).
Data on sociodemographic and lifestyle variables
were collected through standardized interviews in both
studies. Data on medication use was assessed based on
the packaging of all medication, which the study parti-
cipants had taken during the last week before the in-
vestigation and brought along due to request in advance.
In addition, standardized medical examinations were
carried out and blood samples were collected (Holle
et al., 2005). All participants were prospectively followed
within the KORA framework.
Because of the low incidence of CHD in those younger
than 35 years, we restricted the source populations of the
present studies to persons between 35 and 74 years at
baseline. Further exclusion criteria consisted of missing
blood samples, withdrawn consent, double examinations
and prevalent CHD, yielding two cohorts of interest com-
prising 9299 persons in the MONICA/KORA S1–S3 cohort
study and 3289 persons in the KORA S4 cohort study. Be-
cause participants in S3 were followed for a maximum of
14–15 years, we limited the follow‐up time of both studies to
14 years. After the restriction of follow‐up time, a case‐cohort
study was formed in the surveys S1–S3. The case‐cohort
design of the present study has been described in detail be-
fore (Huth et al., 2020; Thorand et al., 2020). Briefly, a ran-
dom sample subcohort of 2163 participants (1154 men and
1009 women) was drawn from the cohort of interest, strati-
fied by sex and survey. The subcohort was extended by all
further cases occurring within 14 years in the cohort of in-
terest. In the following, we excluded persons with missing
values, persons without genotyping informed consent and
persons who failed preimputation genotype quality control
(QC) in both studies. The finally analyzed MONICA/KORA
S1–S3 case‐cohort study consisted of 451 incident CHD cases
and 1488 noncases (“MONICA/KORA trainingset”; median
follow‐up time: 14.0, 25th percentile: 10.3, 75th percentile:
14.0 years). The KORA S4 cohort study included 160 in-
cident CHD cases and 2749 noncases (“KORA testset”;
median follow‐up time: 14.0, 25th percentile: 14.0, 75th
percentile: 14.0). All study individuals are German residents
and carry a German passport. For details on the selection of
participants see Figure 1.
Written informed consent was given by all study
participants, the study protocols were approved by the
Ethics Committee of the Bavarian Chamber of Physi-
cians. The studies were carried out in accordance with
the Declaration of Helsinki.
2.2 | Assessment of prevalent and
incident CHD
The outcome CHD was a combined endpoint of nonfatal
myocardial infarction as well as coronary death and
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sudden death (International Classification of Disease 9th
Revision: 410–414 and 798).
Until December 2000, the diagnosis of a major, nonfatal
myocardial infarction and coronary death was based on the
MONICA algorithm (H. Tunstall‐Pedoe et al., 1994) in
which a diagnosis of a major CHD event was based on
symptoms, cardiac enzymes (creatine kinase, aspartate
aminotransferase, and lactate dehydrogenase), serial chan-
ges from 12‐lead electrocardiograms (ECGs) evaluated by
Minnesota coding (Prineas et al., 1982), necropsy results
and history of CHD in fatal cases. Since January 1, 2001, the
diagnosis of myocardial infarction was based on the Eur-
opean Society of Cardiology and American College of
Cardiology criteria (Alpert et al., 2000).
Incident events were identified through follow‐up
questionnaires or through the MONICA/KORA myo-
cardial infarction registry, which monitors the occur-
rence of all in‐ and out of‐hospital fatal and nonfatal
myocardial infarctions among the 25–74‐year‐old
inhabitants of the study region (Löwel et al., 1991).
Follow‐up questionnaires were sent to all MONICA/
KORA S1–S3 study participants in 1997/1998, 2002/2003,
and 2008/2009 and to the KORA S4 study participants in
2008/2009 and 2016. The MONICA/KORA myocardial
infarction registry covers the study region only. There-
fore, subjects who had moved outside the study area re-
ported incident events through follow‐up questionnaires
sent to their new addresses, which were traced by ad-
dress research. Additionally, all participants from S1
were invited to participate in a follow‐up examination in
1987/1988. For the KORA S4 study participants, two
follow‐up examinations were conducted in 2006–2008
and 2013/2014. Initially identified self‐reported incident
cases and the self‐reported date of diagnosis not covered
by the MONICA/KORA myocardial infarction registry,
were validated by hospital records or by contacting the
patient's treating physician. Deaths from myocardial in-
farction were validated by death certificates, autopsy
FIGURE 1 Flowchart showing sample
sizes and reasons for exclusions. CHD, coronary
heart disease; QC, quality control
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reports, chart reviews, or information from the last
treating physician.
2.3 | Genotyping and assessment of risk
score variables used for benchmarking
Details on genotyping, genetic QC, and genetic imputa-
tion can be found in Supporting Information Methods,
Table S1, and Figure S1.
Genetic information was added to two reference clinical
models: (1) age, sex, and survey; (2) sex, survey, and the FRS
variables according to D'Agostino et al. (2008) with a minor
modification. The original FRS contains the variables
age, total cholesterol, high‐density lipoprotein (HDL)
cholesterol, systolic blood pressure, antihypertensive medi-
cation use, diabetes status, and current smoking. All metric
variables, except for age, were naturally logarithmically (ln)
transformed and (0,1)‐standardized. Prevalent diabetes at
baseline was defined as any type of self‐reported diabetes
that could be validated by the responsible physician or
medical chart review or as current self‐reported use of
glucose‐lowering medication. As a minor modification, we
included former smokers in addition to current smokers as a
separate category and used never smokers as the reference
category. As we determined the combined hazard for men
and women, we additionally included sex as a predictor
variable, as well as a survey indicator, to account for the
study design. During baseline examinations, a venous blood
sample was collected while sitting. Samples were centrifuged
within 120min, refrigerated at 4–8°C and shipped on re-
frigerant packaging within 2–4 h to the laboratory of the
Augsburg Central Hospital (now university hospital of
Augsburg) for measurement of serum HDL cholesterol and
total cholesterol (routine enzymatic method cholesterol oxi-
dase phenol 4‐aminoantipyrine peroxidase; Boehringer
Mannheim [Roche from 1997 on]). HDL cholesterol, total
cholesterol as well as several other collected biomarkers and
variables (not used in the present analyses) had some
missing values in the MONICA/KORA S1–S3 case‐cohort
study (HDL and total cholesterol: 0.04%). Therefore, to en-
able unbiased analyses and to use the available data as effi-
ciently as possible, we replaced missing values using 20‐fold
multiple imputations by chained equations (MICE) (R ver-
sion 3.2.3 and R package MICE version 2.25 [van Buuren &
Groothuis‐Oudshoorn, 2011; van Buuren et al., 1999]). As
there was only a small number of missing values in the
KORA S4 cohort study, we excluded persons with missing
values from the KORA testset (Figure 1).
2.4 | Compared genetic models—Main
analyses
The prediction performance of all main analysis models
was evaluated in the KORA testset based on regression
coefficients (ln‐transformed hazard ratios) estimated in
the MONICA/KORA trainingset (Figure 2). We com-
pared three different approaches to take genetic in-
formation into account. The first two were based on all
Metabochip SNPs published to be genome‐wide sig-
nificantly (p< 5 × 10−8) associated with CHD. These
were extracted from the literature received by a sys-
tematic Pubmed literature search on January 21, 2019,
using the terms (metabochip OR cardiochip OR cardio-
metabochip). In the first approach, we used these SNPs
to build a weighted GRS (GRSMetabo). In the second ap-
proach, we selected the most predictive SNPs from the
FIGURE 2 Analyses workflow. GRS, genetic risk score; PL, priority‐Lasso; SNP, single‐nucleotide polymorphism
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identified genome‐wide significant variants using a
newly developed method called priority‐Lasso, where
reference model variables were prioritized over the SNP
variables (PLMetabo) (Klau et al., 2017, 2018). Prediction
included the unpenalized regression coefficients from the
reference variables together with the shrunk regression
coefficients from the selected SNPs. In the third ap-
proach, we evaluated a weighted GRS published by Gola
et al. (2020) (GRSGola). Briefly, Gola et al. (2020) per-
formed a random forest approach to preselect variants
with corrected Gini importance greater 0. This was fol-
lowed by a hyperparameter tuning to evaluate the opti-
mal number of SNPs and the necessity of weights.
Metabochip data imputed with the Haplotype Reference
Consortium reference panel were used. Their final score
comprised 50,633 weighted SNPs. The authors of the
Gola et al. (2020) publication provided us with variant
names, positions, chromosome numbers, weights,
weighted alleles, and non‐weighted alleles of these
50,633 SNPs, which we used to form GRSGola in the
MONICA/KORA trainingset and the KORA testset.
We added the genetic information of all three ap-
proaches to the two reference models. Regression coeffi-
cients of reference models alone and with the addition of
PLMetabo, GRSMetabo, and GRSGola were calculated in the
MONICA/KORA trainingset and the predictive value of
each model was evaluated in the KORA testset. GRSMetabo
and GRSGola were also evaluated without additional vari-
ables (crude models). Priority‐Lasso regression is not
possible without reference variables of first priority.
Therefore no crude PLMetabo model was estimated.
Only SNPs available in both the MONICA/KORA
trainingset and the KORA testset were used. We ex-
cluded SNPs with Hardy–Weinberg equilibrium (HWE)
test p< 10−20 and minor allele frequency (MAF) < 1% as
in Gola et al. (2020). We further excluded SNPs with
imputation quality R² < 0.3, which was not as strict as in
Gola et al. (2020), where a threshold of 0.8 was chosen, to
keep as much genetic information as possible (Table S2).
2.5 | Compared genetic models—
Sensitivity analyses
Four sensitivity analyses were carried out via 10‐fold
cross‐validation in the KORA testset only (Figure 2
and Table S2).
(1) To verify that the genetic data quality of the MON-
ICA/KORA trainingset was sufficient, GRSGola was
evaluated in the KORA testset, according to the same
protocol as in the main analysis.
(2) Furthermore, to recreate the original risk score by
Gola et al. (2020) as closely as possible, we used all
available SNPs in the KORA testset, including also
those which were unavailable in the MONICA/
KORA trainingset, after exclusion of SNPs with HWE
test p< 10−20, MAF< 1%, and imputation quality
R² < 0.8 (termed GRSGolaOrig).
(3) To take full advantage of the more comprehensive
genetic data in the KORA testset and to compare the
performance of GRSGola to an established benchmark
GRS, we additionally built the weighted GRS, de-
veloped by Khera et al. (2018). This score was derived
from a GWAS and two genome‐wide genotyped va-
lidation studies, imputed with 1000 g reference pa-
nel. It includes 6,630,150 genome‐wide distributed
SNPs. We built this GRS variable after applying two
different QC schemes. On the one hand, we used
only imputation quality R² < 0.3 as an exclusion cri-
terion, as in the original publication by Khera et al.
(2018) (termed GRSKheraOrig).
(4) On the other hand, we applied the same criteria as for
GRSGolaOrig, namely HWE p< 10
−20, MAF< 1%, and
imputation quality R² < 0.8 (termed GRSKheraQCGola).
All GRS variables were added separately to the vari-
ables of the two reference models used for the main
analyses. Crude models were also evaluated.
2.6 | Statistical methods
Descriptive analyses of baseline characteristics were
computed separately for cases and noncases. For the
MONICA/KORA trainingset, weighting was in-
corporated using the survey‐ and sex‐specific sampling
weights to account for the case‐cohort design. Multiple
results of the 20 imputations were summed up as med-
ians for percentiles and arithmetic means for propor-
tions. Descriptive analyses for the MONICA/KORA
trainingset were calculated using SAS (Version 9.4; SAS
Institute Inc).
To assess the association of risk factor variables with
incident CHD, Cox proportional hazard regression was
applied. To take the case‐cohort design into considera-
tion, regression coefficients (ln‐transformed hazard ra-
tios) in the MONICA/KORA trainingset were calculated
using Barlow's weighting method (Barlow et al., 1999).
Standard error estimates for the regression coefficients in
the MONICA/KORA trainingset were obtained from ro-
bust variance estimation (Barlow, 1994). Additional var-
iation due to imputation was incorporated using Rubin's
rules for Model 2 (Rubin, 1987). There were no missing
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values in the Model 1 variables, which had therefore not
been imputed.
Priority‐Lasso, which was used for the selection of
predictive SNP variables, was extended by Barlow's
weighting method to account for the case‐cohort design of
the MONICA/KORA trainingset. Details of priority‐Lasso
have previously been described in Klau et al. (2018).
Briefly, priority‐Lasso is an enhancement of the standard
Lasso method with a fixed block structure of the variables.
Each variable belongs to exactly one block and each of
these blocks is assigned a priority level. Unpenalized Cox
regression is applied to all variables of the first block.
Subsequently, a Lasso regression is conducted among all
variables of the second block, using the linear predictor of
the first step as offset. Through this method, variables
from blocks of lower priority are only included in the
model, if they explain variability that was not explained by
blocks of higher priority. We assigned the variables of our
reference models the first priority (Block 1) and all SNP
variables the second priority (Block 2). The R package
priority‐Lasso (Klau et al., 2017) was used after having
been adapted to the case‐cohort design, which includes
also an adapted glmnet version. The glmnet version can be
downloaded from https://github.com/mu4bu2/glmnet.
The tuning parameter lambda was chosen via 10‐fold
cross‐validation in the MONICA/KORA trainingset. We
used the default cross‐validation procedure as described in
Simon et al. (2011). Briefly, we evaluated 100 different
lambda values, with λmin and λmax defined as in Simon
et al. (2011). Deviance, which uses the partial‐likelihood
for the Cox model, was used as the loss function. That
lambda resulting in the minimal mean cross‐validated
prediction error was selected as the final tuning parameter
and used in the complete MONICA/KORA trainingset for
priority‐Lasso estimations.
To take the uncertainty of genetic imputation into ac-
count, instead of best‐guess genotypes (“hard calls”), the
estimated alternate allele dosage for each SNP was used and
treated as metric quantity. For priority‐Lasso we included the
(0,1)‐standardized dosage of each SNP as a separate variable.
For the construction of all GRS (GRSMetabo, GRSGola,
GRSGolaOrig, GRSKheraOrig, GRSKheraQCGola), dosages were
adapted to the published regression coefficients (two‐dosage,
if the regression coefficient referred to the other allele). The
GRS variables were built by multiplying the adapted dosage
with the published regression coefficient (ln‐transformed
odds ratio) and by summing across all SNPs, followed by
(0,1)‐standardization. Khera et al. (2018) published positive
regression coefficients and therefore solely risk alleles were
weighted. All other published regression coefficients used in
the present analyses were a mixture of positive and negative
values (Deloukas et al., 2013; Gola et al., 2020; Howson
et al., 2017; van der Harst & Verweij, 2018).
The added predictive value of the genetic information
was evaluated by three performance measures: (1) Harrel's
concordance index (C‐index) and the difference between
the reference and the genetically extended C‐indices (delta
C‐index) (Harrell et al., 1982); (2) the category‐free net
reclassification index (Pencina et al., 2011) calculated
overall (cfNRI) and separately for cases (cfNRIcases) and
controls (cfNRIcontr); (3) the absolute integrated dis-
crimination improvement (IDI) and additionally the re-
lative IDI (IDIrel), as the IDI depends on the incidence of
the outcome (Pencina et al., 2010).
The performance measures in the KORA testset were
calculated from the regression coefficients derived in the
MONICA/KORA trainingset. As there were no missing
values in the reference model 1 variables, the linear
predictor was built as usual. The regression coefficients
of Model 2 alone and with extension of GRSMetabo or
GRSGola were averaged over the 20 imputations. Con-
fidence intervals (CIs) were calculated with standard
errors of an approximate normal‐distribution for the
C‐index using the R package compareC (Kang et al.,
2015) and via 1000‐fold percentile bootstrapping for
cfNRI and IDI using the R packages nricens and boot
(Canty & Ripley, 2020; Davison & Hinkley, 1997;
Inoue, 2018); for the PLMetabo—extended reference model
2, it was not possible to take the averaged regression
coefficients due to different tuning parameters in the 20
imputations. Therefore, each performance measure was
calculated separately in each imputation and the results
were combined using Rubin's Rules (Rubin, 1987).
In the cross‐validation of the sensitivity analyses, the
arithmetic mean of all performance measures was cal-
culated over the 10 folds. The CIs of the mean perfor-
mance measures were calculated via 1000‐fold percentile
bootstrapping using the R package boot (Canty &
Ripley, 2020; Davison & Hinkley, 1997).
Test results with two‐sided p< 0.05 were considered
statistically significant and all statistical analyses were
performed with R version 4.0.0 unless specified otherwise.
3 | RESULTS
3.1 | Baseline characteristics
Table 1 shows baseline characteristics of the 451 incident
CHD cases and 1488 noncases of the MONICA/KORA
trainingset and the 160 incident CHD cases and 2749
noncases of the KORA testset. In both studies, the cases
comprised more men than women. They were on average
older and had a higher systolic blood pressure despite a
more frequent use of antihypertensive medication. They
were more likely to have diabetes at baseline and to be
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current or former smokers. Furthermore, the cases had
higher levels of total cholesterol and lower levels of HDL
cholesterol compared to noncases. Medians of GRSGola
and GRSGolaOrig were substantially higher in cases than
in noncases. There were only slight differences in
GRSMetabo, GRSKheraOrig, and GRSKheraQCGola.
3.2 | Literature search for Metabochip
SNPs associated with CHD
Our literature search yielded three studies reporting
genome‐wide significant association results between
Metabochip SNPs and CHD. These were Deloukas et al.
(2013), Howson et al. (2017), and van der Harst and
Verweij (2018) who conducted large‐scale, consecutive
association studies based only or mainly on Metabochip
data. All three studies were extensions of the largest
GWAS meta‐analysis at that time, performed by the
Coronary ARtery DIsease Genomewide Replication and
Meta‐analysis (CARDIoGRAM) Consortium (Schunkert
et al., 2011). We included all Metabochip SNPs that were
reported to be genome‐wide significantly associated with
CHD either directly in one of the three studies, or in cited
studies. The 138 identified SNPs were then used for se-
lection in the priority‐Lasso analysis as well as for
building GRSMetabo, choosing the most recent published
association estimate as weight, as the more recent studies
had the larger sample sizes. The 138 extracted SNPs are
listed with their weight (ln[odds ratio]) in Table S3.
3.3 | Main analyses
The hazard ratios of the reference models, calculated in
the MONICA/KORA trainingset and used for the
TABLE 1 Baseline characteristics of incident CHD cases and noncases in the MONICA/KORA trainingset and the KORA testset
Characteristics
MONICA/KORA trainingseta KORA testset
CHD cases n= 451 Noncases n= 1488 CHD cases n= 160 Noncases n= 2749
Male (%) 73.4 46.9 75.6 46.5
Age (years) 62 (55, 68) 51 (43, 60) 64 (54, 69) 53 (44, 63)
Survey 1 (%) 21.3 28.8 – –
Survey 2 (%) 43.7 36.3 – –
Survey 3 (%) 35.0 35.0 – –
Survey 4 (%) – – 100.0 100.0
Framingham risk score variables
Prevalent diabetes mellitus at baseline (%) 17.7 4.3 20.6 4.6
Systolic blood pressure (mmHg) 144.0 (130.0, 158.0) 130.0 (120.0, 143.0) 140.0 (126.4, 152.2) 128.5 (117.0, 141.5)
Antihypertensive medication use (%) 37.9 14.2 41.3 19.7
Total cholesterol (mg/dl) 253.1 (223.3, 286.0) 233.0 (207.0, 265.9) 238.7 (212.4, 265.7) 229.7 (203.5, 260.2)
HDL cholesterol (mg/dl) 48.0 (40.5, 58.4) 55.3 (45.7, 67.3) 50.0 (41.8, 61.7) 56.2 (45.7, 68.7)
Smoking
Former (%) 36.8 27.3 36.3 33.5
Current (%) 30.8 23.1 28.8 22.7
Never (%) 32.4 49.6 35.0 43.8
Genetic risk scores
GRSMetabo 0.26 (−0.13, 0.68) 0.12 (−0.24, 0.54) 0.22 (−0.21, 0.59) 0.16 (−0.24, 0.54)
GRSGola 4.45 (−0.10, 8.60) 3.15 (−0.67, 6.97) 2.85 (−2.95, 8.04) 0.30 (−5.22, 5.86)
GRSGolaOrig – – 1.42 (−5.41, 6.58) −1.71 (−8.14, 4.60)
GRSKheraOrig – – 17.60 (17.54, 17.67) 17.58 (17.52, 17.64)
GRSKheraQCGola – – 13.85 (13.79, 13.91) 13.83 (13.77, 13.88)
Note: Categorical variables are presented as proportions and continuous variables as medians (25th; 75th percentile).
Abbreviations: CHD, coronary heart disease; GRS, genetic risk score; HDL, high‐density lipoprotein.
aFor the MONICA/KORA trainingset, weighting was incorporated using the survey‐ and sex‐specific sampling weights to account for the case‐cohort design.
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prediction analyses in the KORA testset, are shown in
Table S4. Except for survey and former smoking, all
variables were significantly associated with in-
cident CHD.
In the PLMetabo models, 10 SNPs were selected on top
of Model 1; 7 of these also on top of Model 2 (Table S5).
The GRSMetabo was associated with incident CHD in
the crude model (hazard ratio [95% CI] per SD: 1.2341
[1.1137, 1.3676]) and in Model 1 (1.2126 [1.0766, 1.3659])
but not in Model 2 (1.1300 [0.9989, 1.2784]); Table S6).
The GRSGola was associated with CHD in all three
models (crude: 1.2516 [1.1203, 1.3982]; Model 1: 1.2297
[1.0804, 1.3996]; Model 2: 1.1580 [1.0109, 1.3265];
Table S6).
The prediction performance measures in the KORA
testset are presented in Tables 2 and S7. In the crude
models, the GRSGola yielded a C‐index of 0.5878 [95% CI:
0.5446, 0.6310] and thus performed better than the
GRSMetabo (C‐index: 0.5253 [0.4803, 0.5702]). Generally,
the C‐index is a measure to determine the power of a
model to discriminate between cases and noncases based
on predicted survival probabilities. A C‐index of 0.5 in-
dicates that the model is not able to distinguish between
cases and noncases at all. A C‐index significantly higher
than 0.5 points at a better discrimination ability of the
model than random guessing. On top of both reference
models, there was no evidence that the SNPs that
were selected by priority‐Lasso, or the GRSMetabo im-
proved the prediction. The extended models did not
produce delta C‐indices, cfNRIs nor IDIs significantly
higher than 0. Whereas the delta C‐index compares the
discrimination ability of a reference and an extended








C‐index 0.5253 [0.4803, 0.5702] 0.7537 [0.7189, 0.7886]* 0.7571 [0.7234, 0.7908]* 0.7905 [0.7604, 0.8207]* 0.7920 [0.7622, 0.8219]*
ΔC‐index, cfNRIcases, cfNRIcontr, IDIabs, and IDIrel were not significant (Table S7).
PLMetabob(Model 1: 10 SNPs, Model 2: 7 SNPs)
PLMetabo Model 1 Model 1+ PLMetabo Model 2 Model 2+ PLMetabo
C‐index –b 0.7537 [0.7189, 0.7886]* 0.7459 [0.7109, 0.7809]* 0.7905 [0.7604, 0.8207]* 0.7855 [0.7551, 0.8159]*
ΔC‐index, cfNRIcases, cfNRIcontr, IDIabs, and IDIrel were not significant (Table S7).
GRSGolac(39,570 SNPs)
Performance















ΔC‐index – 0.0136 [0.0067, 0.0205]* 0.0087 [0.0044, 0.0130]*
cfNRI – 0.1817 [0.0280, 0.3341]* 0.1158 [−0.0462, 0.2652]
cfNRIcases – 0.1667 [0.0166, 0.3172]* 0.1761 [0.0253, 0.3219]*
cfNRIcontr – 0.0151 [−0.0225, 0.0516] −0.0603 [−0.0991, −0.0250]*
IDI – 0.0071 [0.0028, 0.0119]* 0.0048 [0.0011, 0.0091]*
IDIrel – 0.1055 [0.0445, 0.1741]* 0.0509 [0.0131, 0.0894]*
Note: Model 1 includes age, sex, survey. Model 2 (Framingham risk score) additionally includes diabetes status, smoking status, systolic blood pressure,
antihypertensive medication, HDL cholesterol, total cholesterol. Performance measures were derived from regression coefficients estimated in the MONICA/
KORA trainingset (Tables S4–S6).
Abbreviations: C‐index, concordance Index; cfNRI, category‐free net reclassification index; CI, confidence interval; GRS, genetic risk score; IDI, independent
discrimination improvement; PL, priority‐Lasso; SNP, single‐nucleotide polymorphism.
aGRSMetabo includes genome‐wide associated Metabochip SNPs available in MONICA/KORA trainingset and KORA testset after exclusion of SNPs with
Hardy–Weinberg equilibrium test p< 10−20, minor allele frequency < 1%, imputation quality R² < 0.3.
bSNPs selected by priority‐Lasso from Metabochip variants genome‐wide significantly associated with CHD in the literature. At least two blocks of variables
with different priorities are necessary to conduct a priority‐Lasso regression.
cGRS from Gola et al. (2020) with all SNPs available in MONICA/KORA trainingset and KORA testset after exclusion of SNPs with Hardy–Weinberg
equilibrium test p< 10−20, minor allele frequency < 1%, imputation quality R² < 0.3.
*Statistical significance at the 5% level.
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model, cfNRI and IDI compare the reclassification ability
of both. The cfNRI describes the proportion of people for
whom the expanded model improved the prediction
(predicted risk higher for cases, lower for noncases). The
IDI quantifies the difference between a change on aver-
age sensitivity and a change on average 1–specificity. In
IDIrel, this difference is considered in relation to the
reference model to avoid dependence on incidence. In
contrast to PLMetabo and GRSGola, the GRSGola in both
models yielded improved C‐indices (Model 2 delta C‐
index: 0.0087 [0.0044, 0.0130]) and IDI estimates (Model
2 IDIrel: 0.0509 [0.0131, 0.0894]). The overall cfNRI
showed an improved reclassification in Model 1, al-
though it was not statistically significant in Model 2.
3.4 | Sensitivity analyses
In the sensitivity analyses that were solely based on data
from the KORA testset (Table 3), the performance of the
cross‐validated GRSGola was slightly higher (C‐index:
0.5881 [0.5435, 0.6299]) compared to the main analyses,
where the regression coefficients were derived from the
MONICA/KORA trainingset (C‐index: 0.5878 [0.5446,
0.6310]; Table 2). Moreover, the cross‐validated pre-
dictive performance of the GRSGola and the GRSGolaOrig,
which differed in the application of QC criteria, were
comparable. The crude GRSGolaOrig yielded a cross‐
validated C‐index of 0.5910 [0.5488, 0.6356]. When added
to the FRS variables, the C‐index improved by 0.0106
[0.0019, 0.0237], the overall cfNRI was 0.2347 [0.0576,
0.4164], and the IDI and IDIrel estimates were 0.0116
[0.0021, 0.0295] and 0.1410 [0.0201, 0.3526], respectively.
The cross‐validated performance measures of
GRSKheraOrig and GRSKheraQCGola were comparable and
yielded similar improved C‐indices and cfNRI estimates
as the GRSGola and GRSGolaOrig, but no significant im-
provement by IDI and IDIrel (Table 3).
4 | DISCUSSION
The present study compared different approaches based
on genetic data to improve CHD prediction beyond the
established FRS variables.
One of our approaches was to select the most pre-
dictive variants among Metabochip SNPs genome‐wide
associated with CHD. We chose the novel priority‐Lasso
algorithm which allowed to select predictive SNP vari-
ables on top of our fixed variables from the FRS, aiming
at highlighting strongly predictive SNPs (Klau
et al., 2018). Their shrunk coefficients counteract over-
fitting and thus are expected to lead to better prediction
results than unpenalized coefficients. However, although
some Metabochip SNPs were selected because they ex-
plained more CHD outcome variability than the re-
ference models alone, they were not able to increase the
prediction accuracy in the KORA testset. The predictive
value of the selected SNPs seemed to be too small.
We also built a weighted GRS including all genome‐
wide associated Metabochip SNPs (GRSMetabo). Here, the
summing of SNP dosages weighted with the respective
published ln(odds ratio) estimates takes differences in
predictive importance of the variants into consideration.
Usage of published weights, instead of estimates from the
own data set, reduces overfitting. Our results indicated
that the exclusive usage of genome‐wide associated Me-
tabochip variants, despite weighting, was not sufficient to
improve the prediction. A similar approach with a pro-
spective cohort and Metabochip data was conducted by
Morris et al. (2016). They evaluated a 53‐SNP GRS
mainly based on variants from Deloukas et al. (2013) and
found minimal incremental utility beyond clinical risk
variables (age, sex, smoking, family history of cardio-
vascular disease, body mass index, blood pressure,
treatment for hypertension, total and HDL cholesterol).
We extended this approach by including further Meta-
bochip variants identified by Howson et al. (2017) and
van der Harst and Verweij (2018) as well as by estimating
the predictive performance in an independent test data
set. Further studies which included GRSs from estab-
lished SNPs not limited to Metabochip data, reported
inconclusive results regarding the added predictive value
for incident cardiovascular diseases (Antiochos
et al., 2016; Beaney et al., 2017; Paynter et al., 2010; Tada
et al., 2016; de Vries et al., 2015). Variables preliminarily
selected from univariable association tests, which is the
approach of most GWAS, do not necessarily perform
optimally in combination. Preselection based on machine
learning algorithms can alternatively be performed
(Boulesteix et al., 2020).
Our third approach was to evaluate a GRS which had
been developed by Gola et al. (2020) in a case‐control
study on coronary artery disease (GRSGola). In this study,
the variants had been preselected using random forest
with variable importance. The score comprises variants
that are not genome‐wide significantly associated with
the disease. We chose this score for comparison, as it had
been derived from Metabochip data, showed very pro-
mising prediction results, and to our knowledge has not
been validated yet. Indeed, the addition of GRSGola sig-
nificantly improved the C‐index, cfNRIcases, IDI, and
IDIrel beyond both reference models.
Due to the limited imputation quality of the Meta-
bochip data in our MONICA/KORA trainingset, we
could not use about 20% of the SNPs included in the
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ΔC‐index – 0.0176 [0.0051, 0.0340]* 0.0109 [0.0019, 0.0236]*
cfNRI – 0.2616 [0.1020, 0.4202]* 0.2107 [−0.0028, 0.3867]
cfNRIcases – 0.1634 [0.0010, 0.3113]* 0.0214 [−0.1954, 0.2153]
cfNRIcontr – 0.0982 [0.0440, 0.1591]* 0.1893 [0.0634, 0.2910]*
IDI – 0.0125 [0.0029, 0.0282]* 0.0093 [0.0006, 0.0247]*
















ΔC‐index – 0.0167 [0.0048, 0.0326]* 0.0106 [0.0019, 0.0237]*
cfNRI – 0.2911 [0.0982, 0.4295]* 0.2347 [0.0576, 0.4164]*
cfNRIcases – 0.1912 [−0.0084, 0.3299] 0.0741 [−0.1221, 0.2652]
cfNRIcontr – 0.0999 [0.0437, 0.1532]* 0.1605 [0.0520, 0.2770]*
IDI – 0.0157 [0.0049, 0.0329]* 0.0116 [0.0021, 0.0295]*
















ΔC‐index – 0.0158 [0.0038, 0.0373]* 0.0105 [0.0018, 0.0259]*
cfNRI – 0.2258 [0.0650, 0.3867]* 0.2036 [0.0523, 0.4222]*
cfNRIcases – 0.1769 [0.0248, 0.3399]* 0.1010 [−0.0512, 0.3254]
cfNRIcontr – 0.0489 [−0.0078, 0.0996] 0.1026 [0.0005, 0.2104]*
IDI – 0.0046 [−0.0011, 0.0171] 0.0059 [−0.0011, 0.0213]
















ΔC‐index – 0.0143 [0.0030, 0.0362]* 0.0098 [0.0014, 0.0252]*
cfNRI – 0.2136 [0.0281, 0.3695]* 0.2397 [0.0727, 0.4293]*
cfNRIcases – 0.1632 [−0.0214, 0.3071] 0.1486 [−0.0389, 0.3410]
cfNRIcontr – 0.0503 [0.0025, 0.0995]* 0.0911 [−0.0018, 0.2040]
(Continues)
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original GRS described by Gola et al. (2020) when we
formed the GRSGola. We, therefore, repeated the analysis
based only on data from our KORA testset where we
could build the GRS nearly identical to the original de-
scription (GRSGolaOrig). The resulting predictive perfor-
mance slightly improved but stayed far below the original
published estimate. The C‐index of GRSGolaOrig in our
study was 0.5910 [95% CI: 0.5488, 0.6356] in the crude
model, although the originally published value was
0.9222 [0.9045, 0.9400]. Our study design differed com-
pared to Gola et al. (2020); we used cohort instead of
case‐control data. The transferability of results based on
prevalent outcome data to incident outcome data might
be limited due to survival bias occurring especially in
studies on highly lethal diseases like CHD (Anderson
et al., 2011). Moreover, we applied Cox proportional
hazard regression instead of logistic regression. However,
these reasons are not likely to explain all of the huge
discrepancies. Further studies are needed to replicate our
results.
Another GRS derived by Khera et al. (2018) in a study
on prevalent coronary artery disease based on genetically
imputed UK BiLEVE Axiom Array (807,411 variants) or
UK Biobank Axiom Array (825,927 variants) data also
yielded promising prediction results in the initial de-
scription. Preselection of variants for this comprehensive
score was done using the LDPred algorithm (Vilhjálms-
son et al., 2015). Like GRSGola it is not limited to genome‐
wide significantly associated variants. We included the
score in our comparison to evaluate whether the pre-
diction accuracy could be further improved without
being limited to Metabochip data. The cross‐validated
C‐index for the model including the GRSKheraOrig, age,
and sex was 0.7752 [0.7443, 0.8029], which was below the
originally published value of 0.81 [0.81, 0.81] (model:
GRS, age, sex, ancestry, genotyping array). The dis-
crepancy may be explained by our usage of prospective
data. Weights and score derivation were both based on
datasets with prevalent outcomes, leading to possible
survival bias (Anderson et al., 2011). Furthermore,
weights were obtained from the CARDIOGRAMplusC4D
GWAS, which only included 77% of participants of Eur-
opean ancestry (Nikpay et al., 2015). Mosley et al. (2020)
validated the GRS developed by Khera et al. (2018) in two
studies on incident CHD using Cox regression. They
achieved C‐indices of 0.549 [0.521, 0.571] and 0.587
[0.532, 0.623] (model: GRS, ancestry), but did not yield
additional predictive value beyond a clinical risk model.
Hindy et al. (2020) found C‐indices of 0.759 [0.724, 0.794]
and 0.756 [0.750, 0.762] (model: age, sex, ancestry, GRS)
in two prospective studies on coronary artery disease
using Cox‐regression. After addition to traditional risk
factors, C‐indices significantly increased from 0.776 to
0.802 and from 0.748 to and 0.768. Dikilitas et al. (2020)
reported improved C‐indices of the Khera GRS beyond a
base model (age‐as‐time‐scale Cox model with sex, site,
ancestry) in three different racial and ethnic groups on
incident CHD (European ancestry: improvement from
0.690 to 0.719). The Khera GRS was additionally eval-
uated by Wünnemann et al. (2019) in two studies on
incident CHD. Using logistic regression, they retrieved
C‐indices of 0.57 [0.51, 0.62] and 0.60 [0.51, 0.62] in models
which included age, sex, and ancestry in addition to the
GRS. Finally, Aragam et al. (2020) computed the Khera
GRS in three cohorts on prevalent coronary artery disease
yielding crude C‐indices ranging from 0.59 to 0.61.
To directly compare the scores derived by Gola et al.









IDI – 0.0038 [−0.0012, 0.0157] 0.0056 [−0.0011, 0.0204]
IDIrel – 0.0739 [−0.0235, 0.3782] 0.0692 [−0.0136, 0.2696]
Note: Model 1 includes age, sex, survey. Model 2 (Framingham risk score) additionally includes diabetes status, smoking status, systolic blood pressure,
antihypertensive medication, HDL cholesterol, total cholesterol. Calculations are based only on data from KORA testset.
Abbreviations: C‐index, concordance Index; cfNRI, category‐free net reclassification index; CI, confidence interval; GRS, genetic risk score; IDI, independent
discrimination improvement; PL, priority‐Lasso; SNP, single‐nucleotide polymorphism.
aGRS from Gola et al. (2020) with all SNPs available in MONICA/KORA trainingset and KORA testset after exclusion of SNPs with Hardy–Weinberg
equilibrium test p< 10−20, minor allele frequency < 1%, imputation quality R² < 0.3.
bGRS from Gola et al. (2020) with all SNPs available in KORA testset after exclusion of SNPs with Hardy–Weinberg equilibrium test p< 10−20, minor allele
frequency < 1%, R² < 0.8.
cGRS from Khera et al. (2018) in KORA testset after exclusion of SNPs with imputation quality R² < 0.3.
dGRS from Khera et al. (2018) in KORA testset after exclusion of SNPs with Hardy–Weinberg equilibrium test p< 10−20, minor allele frequency < 1%, R² < 0.8.
*Statistical significance at the 5% level.
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post‐imputation exclusion criteria for both scores
(GRSGolaOrig, GRSKheraQCGola). The GRSKheraQCGola and
the GRSKheraOrig yielded similar results. However, both
were slightly worse than the GRSGolaOrig, which overall
produced the best improvement in the prediction accu-
racy of our comparison. This superiority might partly be
due to the fact that Gola et al. (2020) derived their GRS
from six studies of European descent from the German
population, while Khera et al. (2018) used the more
heterogenous UK Biobank to construct their score.
Nevertheless, comprising more than six million SNPs, the
GRSKheraOrig is considerably more extensive than
GRSGolaOrig with about 50,000 SNPs, pointing out that the
number of SNPs alone is not decisive.
We are aware of four further prospective cardiovas-
cular disease prediction studies that have derived com-
prehensive GRSs including nonsignificant SNPs, all of
them using Cox regression (Abraham et al., 2016; Elliott
et al., 2020; Inouye et al., 2018; Mars et al., 2020). Elliott
et al. (2020) and Inouye et al. (2018) achieved crude
C‐indices of 0.61 and 0.62. When added to traditional
CHD risk factors, their C‐indices increased from 0.76 to
0.78 and from 0.67 to 0.70. In Elliott et al. (2020) this
increase was statistically significant, whereas significance
remained unclear in Inouye et al. (2018). Abraham et al.
(2016) also reported significantly improved C‐indices by
their derived GRS beyond the FRS variables in two pro-
spective studies (C‐indices improved from 0.731 to 0.742
and from 0.848 to 0.866). Elliott et al. (2020) and
Abraham et al. (2016) additionally showed an improve-
ment in overall cfNRI and IDI. Mars et al. (2020) re-
ported an impairment in discrimination after the
addition of their GRS to clinical risk factors (C‐index
decreased from 0.823 to 0.820), but showed an improved
NRI in early‐onset cases and late‐onset controls.
Our study has several strengths. We evaluated two
well‐characterized longitudinal population‐based studies
with a long follow‐up of up to 14 years and physician‐
validated CHD diagnoses. Our outcome was time‐to‐
event, which enabled us to use survival analysis that is
more informative and therefore more clinically relevant
than the usage of logistic regression (George et al., 2014).
We have developed the analysis plan a priori and fol-
lowed it rigorously. To our knowledge, we are the first to
externally investigate the score derived by Gola et al.
(2020). We accounted for imputation uncertainty by
using estimated posterior allele dosages and not hard
calls. We have conducted an extensive literature search
to find all genome‐wide CHD‐associated Metabochip
variants and weighted them with the ln(odds ratio) de-
rived from the study with the largest sample size.
Although there are various studies examining the pre-
dictive value of genetics (alone or in extension to clinical
risk models), most of them lack truly independent valida-
tion in terms of model fit and predictive performance
measures. As building GRSs usually involves two different
data sets, it is a common misconception to believe that
independent validation has already been performed in most
genetic prediction studies (Choi et al., 2020). So called
“discovery datasets” (usually GWAS) are commonly used to
derive GRSs and to calculate weights. Estimation of re-
gression coefficients (ln[hazard ratio] or ln[odds ratio]) and
performance measures of the GRSs and possible clinical
variables are then derived from the same population, often
called “validation‐” or “testset” (Abraham et al., 2016;
Beaney et al., 2017; Elliott et al., 2020; Inouye et al., 2018;
Iribarren et al., 2016; R. W. Morris et al., 2016; Mosley
et al., 2020; Tada et al., 2016). This makes cross‐validation
or bootstrapping crucial to at least attenuate overfitting of
the GRS (and possible other variables) to the testset (Choi
et al., 2020). However, such approaches are rare (Antiochos
et al., 2016; Müller et al., 2016). To our knowledge, we are
the first to use two independent studies for model fit and
evaluation to calculate the incremental predictive value of
genetic information beyond a clinical risk model in the
context of cardiovascular diseases.
Our study has several limitations. Compared to several
other genetic prediction studies, we are limited in sample
size. In addition, our population is restricted to European
ancestry, and therefore the transferability of our findings
to other ethnicities may be limited. Furthermore, the
MONICA/KORA trainingset was not genome‐wide geno-
typed. Therefore, our main analyses, which followed the
advantageous independent validation approach, were
limited to Metabochip SNPs, while the evaluation of
GRSKheraOrig and GRSKheraQCGola was limited to a cross‐
validation approach in the KORA testset. However, as the
Metabochip has been designed to cover DNA regions en-
riched with CHD‐associated SNPs, we assume that we did
not miss many strongly associated SNPs in our
Metabochip‐based approaches. We could show that
GRSGola, which was derived from Metabochip data only,
was sufficient to improve prediction beyond FRS variables.
A further limitation is that our Metabochip imputation
yielded a worse result compared to the Affymetrix im-
putation of the KORA testset. Generally, this can be ex-
plained by the smaller number of SNPs present on
Metabochip compared to Affymetrix, the uneven scatter-
ing of variants across the genome and the larger propor-
tion of lower frequency variants on Metabochip, which all
makes it harder to impute (Liu et al., 2012). In addition,
our Metabochip genotyped data set had a higher propor-
tion of missing values compared to our Affymetrix geno-
typed data set. Altogether we had to exclude more than
10,000 SNPs due to bad imputation quality (R² < 0.3) for
GRSGola in the MONICA/KORA trainingset. To make sure
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that the quality of the remaining SNPs was sufficient, we
additionally evaluated GRSGola via cross‐validation in the
KORA testset as a sensitivity analysis. Cross‐validated
performance measures were then compared to perfor-
mance measures produced in the KORA testset with the
use of regression coefficients derived in the MONICA/
KORA trainingset. A substantial improvement in cross‐
validated prediction would have indicated that genotyping
quality of the discovery case‐cohort data were not reliable.
However, we could verify that cross‐validation produced
comparable results. All analyses were performed in a fairly
homogeneous population of predominantly Caucasian
individuals with German citizenship and residing in or
near Augsburg. Thus, the participants from the MONICA/
KORA trainingset and the KORA testset are very similar
with regard to ethnic background. The KORA S4 cohort
study has been used in various genome‐wide studies, most
recently in a study by Winkler et al. (2020), where no
evidence of population stratification was found. The same
applies for previous analyses of Metabochip data from
MONICA/KORA including parts of the S1–S3 case‐cohort
(Gaulton et al., 2015; A. P. Morris et al., 2012). Because
our final analyzed samples slightly differ from previous
analyses, we have calculated genomic control inflation
factors and conducted permutation tests in both studies,
which also did not indicate population stratification.
Nevertheless, it has to be mentioned that genome‐wide
coverage of SNPs without enrichment for disease loci is
required to correctly define population outliers, which is
not fully given in the MONICA/KORA trainingset. A
small degree of population stratification in the MONICA/
KORA trainingset, which we might have missed to detect,
would lead to a slight underestimation of the predictive
power of the models in the KORA testset.
In conclusion, the findings of our study confirm
previously published results stating the predictive su-
periority of comprehensive polygenic risk scores that are
not restricted to genome‐wide associated variants. How-
ever, none of our examined strategies added a major
predictive value beyond the FRS variables. We were not
able to confirm the high predictive performance of the
initial reports by Gola et al. (2020) and Khera et al.
(2018). This confirms that weights and variant selection
should be derived from prospective cohorts for incident
disease prediction in future studies to avoid survival bias
and underlines the importance of external validation.
ACKNOWLEDGMENTS
The authors thank Professor Anne‐Laure Boulesteix, In-
stitute for Medical Information Processing, Biometry and
Epidemiology, Ludwig‐Maximilians‐University, Munich,
Germany, for excellent statistical advice. This study was
supported by a research grant from the Else Kröner‐
Fresenius‐Stiftung (2015_A130), grants from the German
Research Foundation (TH‐784/2‐1 and TH‐784/2‐2), from
the Helmholtz Alliance “Aging andMetabolic Programming,
AMPro,” from the German Federal Ministry of Education
and Research to the German Center for Diabetes Research
(DZD), and by the Bavarian State Ministry of Health and
Care through the research project DigiMed Bayern
(www.digimed-bayern.de). The KORA study was initiated
and financed by the Helmholtz Zentrum München – Ger-
man Research Center for Environmental Health, which is
funded by the German Federal Ministry of Education and
Research (BMBF) and by the State of Bavaria. Furthermore,
KORA research was supported within the Munich Center of
Health Sciences (MC‐Health), Ludwig‐Maximilians‐
Universität, as part of LMUinnovativ. Metabochip genotyp-
ing was funded by the German Federal Ministry of Educa-
tion and Research (BMBF), Germany, and the State of
Bavaria through the research project Atherogenomics
(01GS0834). Cornelia Huth was supported in part by in-
tramural funding for Translational & Clinical Projects of the
Helmholtz ZentrumMünchen. Holger Prokisch is supported
by the Free State of Bavaria, Ministry of Health (DigiMed
Bayern). The German Diabetes Center (DDZ) is supported
by the Ministry of Culture and Science of the State of North
Rhine‐Westphalia and the German Federal Ministry of
Health. The sponsors had no further role in study design,
data analysis, data interpretation, writing of the report and
decision to publish the manuscript.
CONFLICT OF INTERESTS
Michael Roden reports personal fees from Eli Lilly, Poxel
S. A. Société, Boehringer‐Ingelheim Pharma, Terra Fir-
ma, Sanofi US, Servier Labatories, Novartis Pharma
GmbH, Fishawack Group, PROSCIENTO, Inc., Target
Pharmasolutions, Gilead Sciences, Kenes Group, Bristol
Myers Squibb, Intercept Pharma, Inventiva, AstraZeneca,
and Allergan GmbH outside the submitted work. Wolf-
gang Koenig reports personal fees from AstraZeneca,
Novartis, Pfizer, The Medicines Company, DalCor,
Kowa, Amgen, Corvidia, Daiichi‐Sankyo, Berlin‐Chemie,
Sanofi, Bristol‐Myers Squibb, and grants and non-
financial support from Singulex, Abbott, Roche Diag-
nostics, and Beckmann outside the submitted work.
Christian Herder reports personal fees from Sanofi and
Lilly, and grants from Sanofi outside the submitted work.
The other authors report no conflict of interests.
DATA AVAILABILITY STATEMENT
The data are subject to national data protection laws and
restrictions were imposed by the Ethics Committee of the
Bavarian Chamber of Physicians to ensure the data
privacy of the participants. The data can be requested
through a project agreement via the online portal KORA.
14 | BAUER ET AL.
passt (https://epi.helmholtz-muenchen.de/). Please con-





Abraham, G., Havulinna, A. S., Bhalala, O. G., Byars, S. G.,
De Livera, A. M., Yetukuri, L., Tikkanen, E., Perola, M.,
Schunkert, H., Sijbrands, E. J., Palotie, A., Samani, N. J.,
Salomaa, V., Ripatti, S., & Inouye, M. (2016). Genomic prediction
of coronary heart disease. European Heart Journal, 37(43),
3267–3278. https://doi.org/10.1093/eurheartj/ehw450
Alpert, J. S., Thygesen, K., Antman, E., & Bassand, J. P. (2000).
Myocardial infarction redefined—A consensus document of
The Joint European Society of Cardiology/American College
of Cardiology Committee for the redefinition of myocardial
infarction. Journal of the American College of Cardiology,
36(3), 959–969. https://doi.org/10.1016/s0735-1097(00)00804-4
Anderson, C. D., Nalls, M. A., Biffi, A., Rost, N. S., Greenberg, S. M.,
Singleton, A. B., Meschia, J. F., & Rosand, J. (2011). The effect of
survival bias on case‐control genetic association studies of highly
lethal diseases. Circulation: Cardiovascular Genetics, 4(2), 188–196.
https://doi.org/10.1161/CIRCGENETICS.110.957928
Antiochos, P., Marques‐Vidal, P., McDaid, A., Waeber, G., &
Vollenweider, P. (2016). Association between parental history
and genetic risk scores for coronary heart disease prediction:
The population‐based CoLaus study. Atherosclerosis, 244,
59–65. https://doi.org/10.1016/j.atherosclerosis.2015.10.104
Aragam, K. G., Dobbyn, A., Judy, R., Chaffin, M., Chaudhary, K.,
Hindy, G., Cagan, A., Finneran, P., Weng, L. C., Loos, R.,
Nadkarni, G., Cho, J. H., Kember, R. L., Baras, A., Reid, J.,
Overton, J., Philippakis, A., Ellinor, P. T., Weiss, S. T., …
Natarajan, P. (2020). Limitations of contemporary guidelines
for managing patients at high genetic risk of coronary artery
disease. Journal of the American College of Cardiology, 75(22),
2769–2780. https://doi.org/10.1016/j.jacc.2020.04.027
Barlow, W. E. (1994). Robust variance estimation for the case‐
cohort design. Biometrics, 50(4), 1064–1072.
Barlow, W. E., Ichikawa, L., Rosner, D., & Izumi, S. (1999). Analysis
of case‐cohort designs. Journal of Clinical Epidemiology, 52(12),
1165–1172. https://doi.org/10.1016/s0895-4356(99)00102-x
Beaney, K. E., Cooper, J. A., Drenos, F., & Humphries, S. E. (2017).
Assessment of the clinical utility of adding common single
nucleotide polymorphism genetic scores to classical risk factor
algorithms in coronary heart disease risk prediction in UK
men. Clinical Chemistry and Laboratory Medicine, 55(10),
1605–1613. https://doi.org/10.1515/cclm-2016-0984
Boulesteix, A. L., Wright, M. N., Hoffmann, S., & König, I. R.
(2020). Statistical learning approaches in the genetic
epidemiology of complex diseases. Human Genetics, 139(1),
73–84. https://doi.org/10.1007/s00439-019-01996-9
Canty, A., & Ripley, B. (2020). boot: Bootstrap R (S‐Plus) Functions.
R package version 1.3‐25.
Choi, S. W., Mak, T. S., & O'Reilly, P. F. (2020). Tutorial: A guide to
performing polygenic risk score analyses. Nature Protocols,
15(9), 2759–2772. https://doi.org/10.1038/s41596-020-0353-1
D'Agostino, R. B., Sr., Vasan, R. S., Pencina, M. J., Wolf, P. A.,
Cobain, M., Massaro, J. M., & Kannel, W. B. (2008). General
cardiovascular risk profile for use in primary care: The
Framingham Heart Study. Circulation, 117(6), 743–753.
https://doi.org/10.1161/CIRCULATIONAHA.107.699579
Damask, A., Steg, P. G., Schwartz, G. G., Szarek, M., Hagström, E.,
Badimon, L., Chapman, M. J., Boileau, C., Tsimikas, S.,
Ginsberg, H. N., Banerjee, P., Manvelian, G., Pordy, R.,
Hess, S., Overton, J. D., Lotta, L. A., Yancopoulos, G. D.,
Abecasis, G. R., Baras, A., & Paulding, C., Regeneron Genetics
Center and the ODYSSEY OUTCOMES Investigators. (2020).
Patients with high genome‐wide polygenic risk scores for
coronary artery disease may receive greater clinical benefit
from alirocumab treatment in the ODYSSEY OUTCOMES
trial. Circulation, 141(8), 624–636. https://doi.org/10.1161/
CIRCULATIONAHA.119.044434
Davison, A., & Hinkley, D. V. (1997). Bootstrap methods and their
applications. Cambridge: Cambridge University Press.
Deloukas, P., Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L.,
Thompson, J. R., Ingelsson, E., Saleheen, D., Erdmann, J.,
Goldstein, B. A., Stirrups, K., Konig, I. R., Cazier, J. B.,
Johansson, A., Hall, A. S., Lee, J. Y., Willer, C. J.,
Chambers, J. C., Esko, T., … Do, R. (2013). Large‐scale
association analysis identifies new risk loci for coronary
artery disease. Nature Genetics, 45(1), 25‐33. https://doi.org/
10.1038/ng.2480
Dikilitas, O., Schaid, D. J., Kosel, M. L., Carroll, R. J., Chute, C. G.,
Denny, J. A., Fedotov, A., Feng, Q., Hakonarson, H.,
Jarvik, G. P., Lee, M., Pacheco, J. A., Rowley, R., Sleiman, P. M.,
Stein, C. M., Sturm, A. C., Wei, W. Q., Wiesner, G. L.,
Williams, M. S., … Kullo, I. J. (2020). Predictive utility of
polygenic risk scores for coronary heart disease in three major
racial and ethnic groups. American Journal of Human Genetics,
106(5), 707–716. https://doi.org/10.1016/j.ajhg.2020.04.002
Dogan, M. V., Grumbach, I. M., Michaelson, J. J., & Philibert, R. A.
(2018). Integrated genetic and epigenetic prediction of coronary
heart disease in the Framingham Heart Study. PLoS One, 13(1),
e0190549. https://doi.org/10.1371/journal.pone.0190549
de de Vries, P. S., Kavousi, M., Ligthart, S., Uitterlinden, A. G.,
Hofman, A., Franco, O. H., & Dehghan, A. (2015). Incremental
predictive value of 152 single nucleotide polymorphisms in the
10‐year risk prediction of incident coronary heart disease: The
Rotterdam Study. International Journal of Epidemiology, 44(2),
682–688. https://doi.org/10.1093/ije/dyv070
Elliott, J., Bodinier, B., Bond, T. A., Chadeau‐Hyam, M., Evangelou, E.,
Moons, K. G. M., Dehghan, A., Muller, D. C., Elliott, P., &
Tzoulaki, I. (2020). Predictive accuracy of a polygenic risk score‐
enhanced prediction model vs a clinical risk score for coronary
artery disease. Journal of the American Medical Association, 323(7),
636–645. https://doi.org/10.1001/jama.2019.22241
Gaulton, K. J., Ferreira, T., Lee, Y., Raimondo, A., Mägi, R.,
Reschen, M. E., Mahajan, A., Locke, A., Rayner, N. W.,
Robertson, N., Scott, R. A., Prokopenko, I., Scott, L. J.,
Green, T., Sparso, T., Thuillier, D., Yengo, L., Grallert, H., &
Wahl, S., DIAbetes Genetics Replication And Meta‐analysis
(DIAGRAM) Consortium. (2015). Genetic fine mapping and
genomic annotation defines causal mechanisms at type 2
diabetes susceptibility loci. Nature Genetics, 47(12), 1415–1425.
https://doi.org/10.1038/ng.3437
BAUER ET AL. | 15
George, B., Seals, S., & Aban, I. (2014). Survival analysis and
regression models. Journal of Nuclear Cardiology, 21(4),
686–694. https://doi.org/10.1007/s12350-014-9908-2
Gola, D., Erdmann, J., Müller‐Myhsok, B., Schunkert, H., & König, I. R.
(2020). Polygenic risk scores outperform machine learning
methods in predicting coronary artery disease status. Genetic
Epidemiology, 44(2), 125–138. https://doi.org/10.1002/gepi.22279
Global Health Estimates 2016. (2018). Deaths by cause, age, sex, by
country and by region, 2000‐2016. Geneva, World Health
Organization. https://www.who.int/healthinfo/global_burden_
disease/estimates/en/
Harrell, F. E., Jr., Califf, R. M., Pryor, D. B., Lee, K. L., & Rosati, R. A.
(1982). Evaluating the yield of medical tests. Journal of the
American Medical Association, 247(18), 2543–2546.
Herder, C., Karakas, M., & Koenig, W. (2011). Biomarkers for the
prediction of type 2 diabetes and cardiovascular disease.
Clinical Pharmacology and Therapeutics, 90(1), 52–66. https://
doi.org/10.1038/clpt.2011.93
Herder, C., Baumert, J., Zierer, A., Roden, M., Meisinger, C.,
Karakas, M., Chambless, L., Rathmann, W., Peters, A.,
Koenig, W., & Thorand, B. (2011). Immunological and
cardiometabolic risk factors in the prediction of type 2 diabetes
and coronary events: MONICA/KORA Augsburg case‐cohort
study. PLoS One, 6(6), e19852. https://doi.org/10.1371/journal.
pone.0019852
Hindy, G., Aragam, K. G., Ng, K., Chaffin, M., Lotta, L. A.,
Baras, A., Drake, I., Orho‐Melander, M., Melander, O.,
Kathiresan, S., & Khera, A. V., Regeneron Genetics Center.
(2020). Genome‐wide polygenic score, clinical risk factors, and
long‐term trajectories of coronary artery disease.
Arteriosclerosis, Thrombosis, and Vascular Biology, 40(11),
2738–2746. https://doi.org/10.1161/ATVBAHA.120.314856
Holle, R., Happich, M., Löwel, H., & Wichmann, H. E., Group, M.
K. S. (2005). KORA—A research platform for population
based health research. Das Gesundheitswesen, 67(Suppl 1),
S19–S25. https://doi.org/10.1055/s-2005-858235
Howson, J. M. M., Zhao, W., Barnes, D. R., Ho, W. K., Young, R.,
Paul, D. S., Waite, L. L., Freitag, D. F., Fauman, E. B.,
Salfati, E. L., Sun, B. B., Eicher, J. D., Johnson, A. D.,
Sheu, W. H. H., Nielsen, S. F., Lin, W. Y., Surendran, P.,
Malarstig, A., Wilk, J. B., … Watkins, H. (2017). Fifteen new
risk loci for coronary artery disease highlight arterial‐wall‐
specific mechanisms. Nature Genetics, 49(7), 1113‐1119.
https://doi.org/10.1038/ng.3874
Huth, C., Bauer, A., Zierer, A., Sudduth‐Klinger, J., Meisinger, C.,
Roden, M., Peters, A., Koenig, W., Herder, C., & Thorand, B.
(2020). Biomarker‐defined pathways for incident type 2
diabetes and coronary heart disease‐a comparison in the
MONICA/KORA study. Cardiovascular Diabetology, 19(1), 32.
https://doi.org/10.1186/s12933-020-01003-w
Inoue, E. (2018). nricens: NRI for Risk Prediction Models with
Time to Event and Binary Response Data. R package version 1.
6. https://CRAN.R-project.org/package=nricens
Inouye, M., Abraham, G., Nelson, C. P., Wood, A. M., Sweeting, M. J.,
Dudbridge, F., Lai, F. Y., Kaptoge, S., Brozynska, M., Wang, T.,
Ye, S., Webb, T. R., Rutter, M. K., Tzoulaki, I., Patel, R. S., Loos, R.,
Keavney, B., Hemingway, H., … Thompson, J., UK Biobank
CardioMetabolic Consortium CHD Working Group. (2018).
Genomic risk prediction of coronary artery disease in 480,000
adults: Implications for primary prevention. Journal of the
American College of Cardiology, 72(16), 1883–1893. https://doi.
org/10.1016/j.jacc.2018.07.079
Iribarren, C., Lu, M., Jorgenson, E., Martinez, M., Lluis‐Ganella, C.,
Subirana, I., Salas, E., & Elosua, R. (2016). Clinical utility of
multimarker genetic risk scores for prediction of incident coronary
heart disease: A cohort study among over 51 000 individuals of
European ancestry. Circulation: Cardiovascular Genetics, 9(6),
531–540. https://doi.org/10.1161/CIRCGENETICS.116.001522
Kang, L., Chen, W., Petrick, N. A., & Gallas, B. D. (2015). Comparing
two correlated C indices with right‐censored survival outcome:
A one‐shot nonparametric approach. Statistics in Medicine,
34(4), 685–703. https://doi.org/10.1002/sim.6370
Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C.,
Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A.,
Ellinor, P. T., & Kathiresan, S. (2018). Genome‐wide polygenic
scores for common diseases identify individuals with risk
equivalent to monogenic mutations. Nature Genetics, 50(9),
1219–1224. https://doi.org/10.1038/s41588-018-0183-z
Khera, A. V., Emdin, C. A., Drake, I., Natarajan, P., Bick, A. G.,
Cook, N. R., Chasman, D. I., Baber, U., Mehran, R.,
Rader, D. J., Fuster, V., Boerwinkle, E., Melander, O., Orho‐
Melander, M., Ridker, P. M., & Kathiresan, S. (2016). Genetic
risk, adherence to a healthy lifestyle, and coronary disease.
New England Journal of Medicine, 375(24), 2349–2358. https://
doi.org/10.1056/NEJMoa1605086
Klau, S., Hornung, R., & Bauer, A. (2017). Prioritylasso: Analyzing
multiple Omics data with an offset approach. R package version
0.2.1. https://CRAN.R-project.org/package=prioritylasso
Klau, S., Jurinovic, V., Hornung, R., Herold, T., & Boulesteix, A. L.
(2018). Priority‐Lasso: A simple hierarchical approach to the
prediction of clinical outcome using multi‐omics data. BMC
Bioinformatics, 19(1), 322. https://doi.org/10.1186/s12859-018-
2344-6
Koenig, W., Khuseyinova, N., Baumert, J., Thorand, B., Loewel, H.,
Chambless, L., Meisinger, C., Schneider, A., Martin, S.,
Kolb, H., & Herder, C. (2006). Increased concentrations of C‐
reactive protein and IL‐6 but not IL‐18 are independently
associated with incident coronary events in middle‐aged men
and women: results from the MONICA/KORA Augsburg case‐
cohort study, 1984‐2002. Arteriosclerosis, Thrombosis, and
Vascular Biology, 26(12), 2745–2751. https://doi.org/10.1161/
01.ATV.0000248096.62495.73
Liu, E. Y., Buyske, S., Aragaki, A. K., Peters, U., Boerwinkle, E.,
Carlson, C., Carty, C., Crawford, D. C., Haessler, J.,
Hindorff, L. A., Marchand, L. L., Manolio, T. A., Matise, T.,
Wang, W., Kooperberg, C., North, K. E., & Li, Y. (2012).
Genotype imputation of Metabochip SNPs using a study‐
specific reference panel of ~4,000 haplotypes in African
Americans from the Women's Health Initiative. Genetic
Epidemiology, 36(2), 107–117. https://doi.org/10.1002/gepi.
21603
Löwel, H., Lewis, M., Hormann, A., & Keil, U. (1991). Case finding,
data quality aspects and comparability of myocardial
infarction registers: Results of a south German register
study. Journal of Clinical Epidemiology, 44(3), 249–260.
https://doi.org/10.1016/0895-4356(91)90036-9
Mars, N., Koskela, J. T., Ripatti, P., Kiiskinen, T. T. J.,
Havulinna, A. S., Lindbohm, J. V., Ahola‐Olli, A., Kurki, M.,
16 | BAUER ET AL.
Karjalainen, J., Palta, P., FinnGen, Neale, B. M., Daly, M.,
Salomaa, V., Palotie, A., Widen, E., & Ripatti, S. (2020).
Polygenic and clinical risk scores and their impact on age at
onset and prediction of cardiometabolic diseases and common
cancers. Nature Medicine, 26(4), 549–557. https://doi.org/10.
1038/s41591-020-0800-0
Mega, J. L., Stitziel, N. O., Smith, J. G., Chasman, D. I.,
Caulfield, M., Devlin, J. J., Nordio, F., Hyde, C., Cannon, C. P.,
Sacks, F., Poulter, N., Sever, P., Ridker, P. M., Braunwald, E.,
Melander, O., Kathiresan, S., & Sabatine, M. S. (2015). Genetic
risk, coronary heart disease events, and the clinical benefit of
statin therapy: An analysis of primary and secondary
prevention trials. Lancet, 385(9984), 2264–2271. https://doi.
org/10.1016/S0140-6736(14)61730-X
Morris, A. P., Voight, B. F., Teslovich, T. M., Ferreira, T.,
Segrè, A. V., Steinthorsdottir, V., Strawbridge, R. J., Khan, H.,
Grallert, H., Mahajan, A., Prokopenko, I., Kang, H. M.,
Dina, C., Esko, T., Fraser, R. M., Kanoni, S., Kumar, A.,
Lagou, V., Langenberg, C., … Price, J. F. (2012). Large‐scale
association analysis provides insights into the genetic
architecture and pathophysiology of type 2 diabetes. Nature
Genetics, 44(9), 981–990. https://doi.org/10.1038/ng.2383
Morris, R. W., Cooper, J. A., Shah, T., Wong, A., Drenos, F.,
Engmann, J., McLachlan, S., Jefferis, B., Dale, C., Hardy, R.,
Kuh, D., Ben‐Shlomo, Y., Wannamethee, S. G.,
Whincup, P. H., Casas, J. P., Kivimaki, M., Kumari, M.,
Talmud, P. J., … Price, J. F., UCLEB Consortium. (2016).
Marginal role for 53 common genetic variants in
cardiovascular disease prediction. Heart, 102(20), 1640–1647.
https://doi.org/10.1136/heartjnl-2016-309298
Mosley, J. D., Gupta, D. K., Tan, J., Yao, J., Wells, Q. S., Shaffer, C. M.,
Kundu, S., Robinson‐Cohen, C., Psaty, B. M., Rich, S. S.,
Post, W. S., Guo, X., Rotter, J. I., Roden, D. M., Gerszten, R. E., &
Wang, T. J. (2020). Predictive accuracy of a polygenic risk score
compared with a clinical risk score for incident coronary heart
disease. Journal of the American Medical Association, 323(7),
627–635. https://doi.org/10.1001/jama.2019.21782
Müller, B., Wilcke, A., Boulesteix, A. L., Brauer, J., Passarge, E.,
Boltze, J., & Kirsten, H. (2016). Improved prediction of
complex diseases by common genetic markers: State of the art
and further perspectives. Human Genetics, 135(3), 259–272.
https://doi.org/10.1007/s00439-016-1636-z
Nikpay, M., Goel, A., Won, H. H., Hall, L. M., Willenborg, C.,
Kanoni, S., Saleheen, D., Kyriakou, T., Nelson, C. P.,
Hopewell, J. C., Webb, T. R., Zeng, L., Dehghan, A., Alver, M.,
Armasu, S. M., Auro, K., Bjonnes, A., Chasman, D. I.,
Chen, S., … Samani, N. J. (2015). A comprehensive 1,000
genomes‐based genome‐wide association meta‐analysis of
coronary artery disease. Nature Genetics, 47(10), 1121–1130.
https://doi.org/10.1038/ng.3396
Okser, S., Pahikkala, T., Airola, A., Salakoski, T., Ripatti, S., &
Aittokallio, T. (2014). Regularized machine learning in the
genetic prediction of complex traits. PLoS Genetics, 10(11),
e1004754. https://doi.org/10.1371/journal.pgen.1004754
Paynter, N. P., Chasman, D. I., Pare, G., Buring, J. E., Cook, N. R.,
Miletich, J. P., & Ridker, P. M. (2010). Association between a
literature‐based genetic risk score and cardiovascular events in
women. Journal of the American Medical Association, 303(7),
631–637. https://doi.org/10.1001/jama.2010.119
Pencina, M. J., & D'Agostino, R. B., Sr., Steyerberg, E. W. (2011).
Extensions of net reclassification improvement calculations to
measure usefulness of new biomarkers. Statistics in Medicine,
30(1), 11–21. https://doi.org/10.1002/sim.4085
Pencina, M. J., D'Agostino, R. B., & Vasan, R. S. (2010). Statistical
methods for assessment of added usefulness of new
biomarkers. Clinical Chemistry and Laboratory Medicine,
48(12), 1703–1711. https://doi.org/10.1515/CCLM.2010.340
Prineas, R. J., Crow, R. S., & Zhang, Z.‐M. (1982). The Minnesota
code manual of electrocardiographic findings: Standards and
procedures for measurement and classification. Wright.
Rubin, D. B. (1987). Multiple imputation for nonresponse in surveys.
Wiley.
Said, M. A., Verweij, N., & van der Harst, P. (2018). Associations of
combined genetic and lifestyle risks with incident
cardiovascular disease and diabetes in the UK Biobank
Study. JAMA Cardiology, 3(8), 693–702. https://doi.org/10.
1001/jamacardio.2018.1717
Schunkert, H., König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L.,
Holm, H., Preuss, M., Stewart, A. F., Barbalic, M., Gieger, C.,
Absher, D., Aherrahrou, Z., Allayee, H., Altshuler, D.,
Anand, S. S., Andersen, K., Anderson, J. L., Ardissino, D.,
Ball, S. G., … Ziegler, A. (2011). Large‐scale association analysis
identifies 13 new susceptibility loci for coronary artery disease.
Nature Genetics, 43(4), 333–338. https://doi.org/10.1038/ng.784
Schwarze, K., Buchanan, J., Taylor, J. C., & Wordsworth, S. (2018).
Are whole‐exome and whole‐genome sequencing approaches
cost‐effective? A systematic review of the literature. Genetics in
Medicine, 20(10), 1122–1130. https://doi.org/10.1038/gim.
2017.247
Simon, N., Friedman, J., Hastie, T., & Tibshirani, R. (2011).
Regularization paths for Cox's proportional hazards model via
coordinate descent. Journal of Statistical Software, 39(5), 1–13.
https://doi.org/10.18637/jss.v039.i05
Tada, H., Melander, O., Louie, J. Z., Catanese, J. J., Rowland, C. M.,
Devlin, J. J., Kathiresan, S., & Shiffman, D. (2016). Risk prediction
by genetic risk scores for coronary heart disease is independent of
self‐reported family history. European Heart Journal, 37(6),
561–567. https://doi.org/10.1093/eurheartj/ehv462
Thorand, B., Kolb, H., Baumert, J., Koenig, W., Chambless, L.,
Meisinger, C., Illig, T., Martin, S., & Herder, C. (2005).
Elevated levels of interleukin‐18 predict the development of
type 2 diabetes: Results from the MONICA/KORA Augsburg
Study, 1984‐2002. Diabetes, 54(10), 2932–2938. https://doi.org/
10.2337/diabetes.54.10.2932
Thorand, B., Zierer, A., Buyukozkan, M., Krumsiek, J., Bauer, A.,
Schederecker, F., Sudduth‐Klinger, J., Meisinger, C.,
Grallert, H., Rathmann, W., Roden, M., Peters, A., Koenig, W.,
Herder, C., & Huth, C. (2020). A panel of six biomarkers
significantly improves the prediction of type 2 diabetes in the
MONICA/KORA study population. Journal of Clinical
Endocrinology and Metabolism, 106, 1647. https://doi.org/10.
1210/clinem/dgaa953
Tunstall‐Pedoe, H., WHO MONICA Project Principal Investigators.
(1988). The World Health Organization MONICA Project
(monitoring trends and determinants in cardiovascular
disease): A major international collaboration. Journal of
Clinical Epidemiology, 41(2), 105–114. https://doi.org/10.
1016/0895-4356(88)90084-4
BAUER ET AL. | 17
Tunstall‐Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D.,
Rajakangas, A. M., & Pajak, A. (1994). Myocardial infarction
and coronary deaths in the World Health Organization
MONICA Project. Registration procedures, event rates, and
case‐fatality rates in 38 populations from 21 countries in four
continents. Circulation, 90(1), 583–612. https://doi.org/10.
1161/01.cir.90.1.583
Vilhjálmsson, B. J., Yang, J., Finucane, H. K., Gusev, A.,
Lindström, S., Ripke, S., Genovese, G., Loh, P. R., Bhatia, G.,
Do, R., Hayeck, T., Won, H. H., Kathiresan, S., Pato, M.,
Pato, C., Tamimi, R., Stahl, E., … Price, A. L., Schizophrenia
Working Group of the Psychiatric Genomics Consortium,
Discovery, Biology, and Risk of Inherited Variants in Breast
Cancer (DRIVE) study. (2015). Modeling linkage
disequilibrium increases accuracy of polygenic risk scores.
American Journal of Human Genetics, 97(4), 576–592. https://
doi.org/10.1016/j.ajhg.2015.09.001
Voight, B. F., Kang, H. M., Ding, J., Palmer, C. D., Sidore, C.,
Chines, P. S., Burtt, N. P., Fuchsberger, C., Li, Y., Erdmann, J.,
Frayling, T. M., Heid, I. M., Jackson, A. U., Johnson, T.,
Kilpeläinen, T. O., Lindgren, C. M., Morris, A. P., Prokopenko, I.,
Randall, J. C., … Boehnke, M. (2012). The Metabochip, a custom
genotyping array for genetic studies of metabolic, cardiovascular,
and anthropometric traits. PLoS Genetics, 8(8), e1002793. https://
doi.org/10.1371/journal.pgen.1002793
van Buuren, S., & Groothuis‐Oudshoorn, K. (2011). Mice:
Multivariate imputation by chained equations in R. Journal
of Statistical Software, 45(3), 1–67.
van Buuren, S., Boshuizen, H. C., & Knook, D. L. (1999). Multiple
imputation of missing blood pressure covariates in survival
analysis. Statistics in Medicine, 18(6), 681–694. https://doi.org/
10.1002/(sici)1097-0258(19990330)18:63.0.co;2-r
van der Harst, P., & Verweij, N. (2018). Identification of 64 novel
genetic loci provides an expanded view on the genetic architecture
of coronary artery disease. Circulation Research, 122(3), 433–443.
https://doi.org/10.1161/CIRCRESAHA.117.312086
Ward‐Caviness, C. K., Xu, T., Aspelund, T., Thorand, B.,
Montrone, C., Meisinger, C., Dunger‐Kaltenbach, I., Zierer, A.,
Yu, Z., Helgadottir, I. R., Harris, T. B., Launer, L. J., Ganna, A.,
Lind, L., Eiriksdottir, G., Waldenberger, M., Prehn, C.,
Suhre, K., Illig, T., … Peters, A. (2017). Improvement of
myocardial infarction risk prediction via inflammation‐
associated metabolite biomarkers. Heart, 103(16), 1278–1285.
https://doi.org/10.1136/heartjnl-2016-310789
Wetterstrand, K. A. (2020). DNA sequencing costs: Data from the
NHGRI Genome Sequencing Program (GSP). www.genome.
gov/sequencingcostsdata
Winkler, T. W., Grassmann, F., Brandl, C., Kiel, C., Günther, F.,
Strunz, T., Weidner, L., Zimmermann, M. E., Korb, C. A.,
Poplawski, A., Schuster, A. K., Müller‐Nurasyid, M.,
Peters, A., Rauscher, F. G., Elze, T., Horn, K., Scholz, M.,
Cañadas‐Garre, M., McKnight, A. J., … Weber, B. (2020).
Genome‐wide association meta‐analysis for early age‐related
macular degeneration highlights novel loci and insights for
advanced disease. BMC Medical Genomics, 13(1), 120. https://
doi.org/10.1186/s12920-020-00760-7
Wünnemann, F., Sin Lo, K., Langford‐Avelar, A., Busseuil, D.,
Dube, M. P., Tardif, J. C., & Lettre, G. (2019). Validation of
Genome‐Wide Polygenic Risk Scores for Coronary Artery
Disease in French Canadians. Circulation. Genomics and
Precision Medicine, 12(6), e002481. https://doi.org/10.1161/
CIRCGEN.119.002481
SUPPORTING INFORMATION
Additional Supporting Information may be found online
in the supporting information tab for this article.
How to cite this article: Bauer, A., Zierer, A.,
Gieger, C., Büyüközkan, M., Müller‐Nurasyid, M.,
Grallert, H., Meisinger, C., Strauch, K., Prokisch,
H., Roden, M., Peters, A., Krumsiek, J., Herder, C.,
Koenig, W., Thorand, B., & Huth, C. (2021).
Comparison of genetic risk prediction models to
improve prediction of coronary heart disease in
two large cohorts of the MONICA/KORA study.
Genetic Epidemiology, 1–18.
https://doi.org/10.1002/gepi.22389
18 | BAUER ET AL.
